Specialty Pharma Journal Specialty, Precision & Technology
WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, presented an update on its long-term mouse genome editing and delivery studies and shared new, first-time data in rat models demonstrating consistent dose-dependent …
Tag Archives: CRISPR=Cas9
May, 2017
April, 2015
-
2 April
Caribou Biosciences Raises $11 Million to Advance its CRISPR-Cas9 Technology
California-based Caribou Biosciences, one of the upstart leaders in developing CRISPR-Cas9 technologies for precision cell engineering, has closed an $11 million Series A financing round. The group of investors include pharma giant Novartis, Fidelity Biosciences, Mission Bay Capital, 5 Prime Ventures and an undisclosed strategic partner. Additionally, Dr. Jennifer Doudna, …